4 completed, 2 recruiting, 2 unknown. 4 Phase 4, 3 Phase 3, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Recruiting 2, Unknown 2 |
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow Naltrexone-Bupropion combination: new trials by email Literature Review of Naltrexone-Bupropion combination trials Research Report on Naltrexone-Bupropion combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder Group Therapy Program, semaglutide, Phentermine-Topiramate - Bipolar I Disorder, Bipolar II Disorder | Phase 4 | Recruiting | Mayo Clinic | 100 | 2026-01-19 | 2026-03-11 |
| Weight Loss Study: Genetics and Response to Naltrexone/Bupropion Naltrexone-Bupropion Combination - Obesity | Phase 4 | Recruiting | Columbia University | 120 | 2023-06-08 | 2026-06-10 |
| Use of Mysimba in Patients With Weight Regain After Bariatric Surgery Naltrexone-Bupropion Combination - Obesity, Morbid, Bariatric Surgery Candidate | Phase 4 | Unknown | Zuyderland Medisch Centrum | 116 | 2023-03-21 | 2023-05-30 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo - Obesity | Phase 3 | Completed | Yale University | 84 | 2022-01-13 | 2026-09-21 |
| Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Liraglutide 6 MG/ML [Saxenda], Naltrexone-Bupropion Combination - Obesity, Blood Pressure | Phase 4 | Unknown | National and Kapodistrian University of Athens | 40 | 2020-09-08 | 2020-10-08 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy NB medication (Naltrexone Bupropion combination), Placebo - Binge-Eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 68 | 2017-08-28 | 2024-02-02 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo - Binge-eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 136 | 2017-02-27 | 2023-03-08 |
| Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo Naltrexone and bupropion combination, Pill Placebo - Binge Eating Disorder | Not applicable | Completed | Yale University | 22 | 2014-12-01 | 2017-12-22 |
Obesity (6) · Binge-Eating Disorder (3) · Weight Loss (2) · Bipolar Disorder (1) · Medication Adherence (1) · Obesity, Morbid (1) · Psychotic Disorders (1)
Yale University (4) · Columbia University (1) · Mayo Clinic (1) · National and Kapodistrian University of Athens (1) · Zuyderland Medisch Centrum (1)
United States (6) · Greece (1) · Netherlands (1)
Alexandros Kokkinos, MD, PhD (1) · Carlos Grilo, PhD (1) · Carlos M Grilo, Ph.D. (1) · Carlos M Grilo, PhD (1) · Jan Willem Greve, MD, PhD, professor (1) · Judith Korner, MD,PhD (1) · Mark A Frye, M.D. (1) · Valentina Ivezaj, Ph.D. (1)
PMID 33218742, PMID 36285406, PMID 37418844
R01DK049587 (2), R01DK125650 (1), R01DK132527 (1)